New York, June 5, 2026, 04:15 (EDT)
- Medline ended Thursday at $34.45, steady after tumbling earlier in the week on an FDA-triggered selloff.
- Medline’s plant in Waukegan, Illinois, had drug-manufacturing quality lapses, according to the FDA’s latest warning letter.
- Baird lowered its price target to $45 from $57, but still has an Outperform rating.
Medline Inc. MDLN faces more pressure Friday, as the company picked up another warning letter from U.S. regulators. It’s the second in two months, and it again puts Medline’s quality control in focus after its recent IPO. Shares finished Thursday at $34.45, little changed on the day. Latest quote was down 0.06% from the previous close.
Medline’s timing is in focus. The company made its Nasdaq debut in December, pulling off the biggest IPO of 2025. Now, investors are checking if Medline’s hospital supply business is big enough to push through regulatory talk, tariff challenges and post-IPO selling. Shares hold above the $29 IPO price, but that’s still far from the $41 finish on day one.
FDA flagged Medline’s drug plant in Waukegan, Illinois, for major lapses in a warning letter dated May 28 and posted this week. The agency said the site had multiple breaches of CGMP standards, pointing to recurring cases of microbial contamination, poor investigations and problems with cleaning.
FDA said Medline found Bacillus cereus in finished drug samples about nine times from June 2023 to August 2025, and in at least five samples from its manufacturing area since January 2025. The agency said Medline’s weak investigations and missed corrective steps could pose a patient-safety risk.
Medline said it made “significant improvements” to production and plant operations after an inspection in Waukegan, according to Reuters on Wednesday. The comments came after a new FDA warning, which followed a similar FDA notice in April about faulty syringes used in heart procedures. Medline also said it is working with the FDA not only at the Waukegan site but at other drug-manufacturing locations. Reuters
Wall Street took notice. Baird’s Eric Coldwell trimmed his price target on the stock to $45 from $57, keeping his Outperform call. He pointed to the FDA warning letter and macro uncertainty weighing on the shares.
Coldwell called the new warning “not a welcomed series of events” and said it “doesn’t look great,” but he also said he didn’t expect a big earnings impact. He thinks Medline will deal with the issue. TipRanks
Medline posted Q1 net sales of $7.4 billion, up 10.7%. Net income came in at $239 million, down 25.8%. Adjusted EBITDA dropped 10.6% to $776 million. Medline lifted its 2026 organic sales growth target, now at 8.5% to 9.5%.
Competitive context is tied to how Medline’s valuation is debated. Medline, in a recent SEC filing, included Baxter International, Becton Dickinson and Owens & Minor in its peer group for compensation benchmarking. That means investors are lining it up next to larger healthcare-products and distribution companies.
The risk is the FDA process could drag on or be pricier than expected by analysts. The agency has requested independent risk checks, timelines for fixes, and more work on contamination controls. It also warned that not fixing these issues could mean seizure, an injunction, frozen export certificates, or held-up approvals for the plant.
Right now, the stock is straddling two narratives. On one side, there’s a sizable, recurring medical-supplies operation that keeps turning in double-digit sales growth. On the other, the company is still fresh to public markets and has already picked up two FDA warnings before its first year is even halfway over. Investors will decide Friday if this is just noise that can be fixed, or if Medline’s post-IPO valuation gets hit harder.
